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Abstract
Background:  CTLA-4 was initially described as a membrane-bound molecule that inhibited
lymphocyte activation by interacting with B7.1 and B7.2 molecules on antigen presenting cells.
Alternative splicing of mRNA encoding the CTLA-4 receptor leads to the production of a molecule
(sCTLA-4) that lacks a membrane anchor and is therefore secreted into the extracellular space.
Despite studies finding that people with autoimmune disease more frequently express high levels
of sCTLA-4 in their blood than apparently healthy people, the significance of these findings is
unclear.
Methods: Molecules isolated from blood using CTLA-4 specific antibodies were analyzed with
ligand binding assays, mass spectroscopy, and biochemical fractionation in an effort to increase our
understanding of CTLA-4 immunoreactive material.
Results: Mass spectroscopy analysis of the molecules recognized by multiple CTLA-4-specific
antibodies failed to identify any CTLA-4 protein. Even though these molecules bind to the CTLA-
4 receptors B7.1 and B7.2, they also exhibit properties common to immunoglobulins.
Conclusion: We have identified molecules in blood that are recognized by CTLA-4 specific
antibodies but also exhibit properties of immunoglobulins. Our data indicates that what has been
called sCTLA-4 is not a direct product of the CTLA-4 gene, and that the CTLA-4 protein is not
part of this molecule. These results may explain why the relationship of sCTLA-4 to immune
system activity has been difficult to elucidate.
Background
Alternate splicing of the CTLA-4 mRNA transcript can give
rise to at least three mRNA species that encode different
polypeptides [1]. The most well characterized of these is a
type I transmembrane protein (CTLA-4-TM) expressed on
activated T-lymphocytes [2,3]. CTLA-4-TM is a co-receptor
for the B7.1 (CD80) and B7.2 (CD86) molecules
expressed on antigen presenting cells [4,5]. CTLA-4-TM
inhibits immune activity in multiple ways. It regulates sig-
naling through the T-cell receptor [6,7], induces expres-
sion of immunoregulatory factors such as TGF-β and
ICAM-1 [8,9], alters the organization of the immunologi-
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cal synapse [10], increases tryptophan catabolism by anti-
gen presenting cells [11,12] and binds B7.1 and B7.2
preventing activation of lymphocytes through the costim-
ulatory lymphocyte receptor CD28 [13]. Another tran-
script of the CTLA-4 gene encodes a molecule lacking the
transmembrane domain, thus producing a soluble CTLA-
4 polypeptide referred to as sCTLA-4 [14,15]. Like CTLA-
4-TM, sCTLA-4 appears to bind B7.1 and B7.2, and may
have immunomodulatory properties [15-17]. Finally, a
variant transcript [18] has been identified in mouse
(although not humans) that encodes a membrane-span-
ning molecule with an intact cytoplasmic tail, but lacks
the extracellular domain. As such, the molecule does not
bind the B7 family ligands [19] and has been referred to
as ligand-independent CTLA-4 (liCTLA-4).
The expression of these three CTLA-4 transcripts and their
polypeptide products has been associated with immu-
noregulatory function, and differences in their expression
have been associated with immune-mediated disease. For
example, CTLA-4 knockout mice express none of the pos-
sible alternate transcripts and show a profound lympho-
proliferative disorder with fatal multiorgan destruction
[20,21]. Although it is commonly believed that the
absence of the CTLA-4-TM transcript is solely responsible
for the observed immunological disorder in CTLA-4-
knockout mice, the role(s) of the other transcripts have
not been studied as intensively. LiCTLA-4 may have
immunoregulatory functions, as transfection of it into
CTLA-4 deficient T cells partially corrects the tendency for
hyperresonsiveness [19], and the liCTLA-4 transcript has
been associated with the development of insulin depend-
ent diabetes mellitus in the NOD mouse [18]. Finally, a
variety of reports implicate a role for sCTLA-4 in human
autoimmune disease. The CT60 single nucleotide poly-
morphism of the CTLA-4 gene has been associated with
autoimmunity and with reduced levels of the sCTLA-4
transcript [18]. Various studies have demonstrated ele-
vated levels of the sCTLA-4 protein in the blood of
patients with a variety of immunologically mediated dis-
eases including autoimmune thyroid disease [22], sys-
temic lupus erythematosis [23,24], cutaneous systemic
sclerosis [25], allergic asthma [26,27], and psoriasis vul-
garis [28]. This apparent inverse relationship between lev-
els of sCTLA-4 mRNA and circulating levels of the sCTLA-
4 protein is not understood.
Several years ago, we [22] and others [14] described
immunoassays for the detection of sCTLA-4 in human
plasma. Presumably, such material was the gene product
of the sCTLA-4 transcript; however, this was never for-
mally proven. In order to characterize sCTLA-4 in human
blood, we performed biochemical analyses of blood-
derived molecules that are recognized by multiple CTLA-
4-specific antibodies. Our results suggest that the immu-
noreactive material in human blood is not the direct prod-
uct of the sCTLA-4 alternate transcript and has several
biochemical features of human immunoglobulin. In
addition, CTLA-4 immunoreactive material from human
plasma binds the B7.1 and B7.2 proteins, and may have
immunomodulatory function.
Methods
Monoclonal Antibodies and fusion proteins
The following monoclonal antibodies against CTLA-4
(CD152) were used in these studies: BNI3 (BD Pharmin-
gen, SanDiego, CA), AS32 and AS33 (Antibody Solutions,
Palo Alto, CA), are monoclonal antibodies that recognize
extracellular epitopes in the CTLA-4 molecule. The
MOPC-21C antibody (Sigma-Aldrich, St. Louis, MO) was
used as a negative control. ELISA assays for CTLA-4 were
done as described previously [25]. B7.1-Ig (CD-80) and
B7.2-Ig (CD86) fusion proteins (R&D Systems, Minneap-
olis, MN) were biotinylated with the use of a commer-
cially available kit (Pierce Immunochemical, Rockford,
IL). The Muc18-Ig protein (Muc-Ig) fusion protein was
produced by transfecting CHO cells with a commercially
available plasmid (Novagen) encoding a Muc18-Ig fusion
as described [15,29].
Purification of blood-derived sCTLA-4
Plasma samples used in these studies were obtained from
humans undergoing therapeutic plasmapheresis for
myasthenia gravis. Documented informed consent was
obtained for each of the subjects enrolled in this study.
This study was performed under the oversight of the Insti-
tutional Review Board of Aurora Health Care (Protocol #
L-04-35E). Plasma was frozen at -20°C until use. 200 mls
of plasma were diluted with 20 mM Tris-HCl in water
until the pH of the solution reached 6.8. Typically this
required a mixture 1 volume of plasma to 9 volumes of 20
mM Tris-HCl. This mixture was then passed through a col-
umn containing 300 mls of Q sepharose (GE healthcare).
Flow through was collected and solid ammonium sulfate
was added to create a 45% saturated solution. After over-
night incubation at 4°C, precipitate was collected by cen-
trifugation at 1,800 g for 15 minutes. The pelleted
material was resuspended in 20 mls of phosphate buff-
ered saline (PBS, pH 7.4) and dialyzed using a 1 kDa
molecular weight dialysis tubing in PBS with 2 buffer
exchanges. This material was passed over a 2 ml column,
linked to the MOPC-21 monoclonal antibody using the
Pierce Aminolink Plus Immobilization kit, and flow
through was then passed over a column containing the
antibody AS32. Material was eluted from the AS32 col-
umn using elution buffer (Pierce) and collected in 1 ml
fractions.
Blood-derived sCTLA-4 binding to B7.1-Ig and B7.2-Ig
96 well ELISA plates were coated with 100 ul of fractions
collected from the AS32 column overnight at 4°C. After
coating, plates were washed and incubated with 250 μlBMC Immunology 2009, 10:51 http://www.biomedcentral.com/1471-2172/10/51
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block solution (PBS containing 1% w/v bovine serum
albumin and 5% w/v sucrose) for 1 hour at room temper-
ature to block nonspecific protein binding sites. Blocked
wells were incubated with the biotinylated proteins B7.1-
Ig, B7.2-Ig, Muc18-Ig, or AS33 at room temperature for 1
hour. Next, wells were washed, incubated with streptavi-
din HRP (Zymed Carlsbad, CA) for 20 minutes and
washed again. TMB (Pierce Immunochemicals) was
added to the wells, the HRP reaction proceeded for
approximately 15 minutes, was stopped by addition of 1N
H2SO4, and absorbance was read during illumination
with light at 450 nm.
Protein A binding of sCTLA-4
Recombinant sCTLA-4, produced as described [22], or
plasma diluted 1:10 with 150 mM NaCl and 10 mM Tris
pH 7.4 (TBS), was passed over a column containing 1 ml
of protein A sepharose (Pierce). Flow through was col-
lected in 1 ml fractions. 10 mls of TBS was passed over the
column to wash unbound material and was collected in 1
ml fractions. Bound material was eluted from the column
in 100 mM glycine pH 3, collected in 1 ml fractions and
neutralized with 100 ul of 10xTBS. Pre-column, flow
through, wash, and eluted fractions were tested in ELISA
for the presence of sCTLA-4.
Gel filtration
1.5 mls of serum was diluted with 1.5 mls of PBS contain-
ing recombinant sCTLA-4, and passed through a column
(1.5 cm diameter) containing approximately 150 ml of
sephacryl S200 (GE healthcare). The first 4 mls were dis-
carded and then 2 ml fractions were collected by hand.
Each fraction was tested for the presence of blood-derived
sCTLA-4 or recombinant sCTLA-4 using elisa assays.
Protein Identification
Identification of proteins from 1D-SDS PAGE was per-
formed by Proteomic Research Services (http://www.next
gensciences.com/LCMSMS.htm. Ann Arbor, MI). Proteins
that eluted from the AS32 column were precipitated in
70% ethanol and pelleted by centrifugation 14,000 rpm
in a microcentrifuge for 5 minutes. The pellet was dis-
solved at room temperature in 5% SDS, 10 M Urea, 10
mM Tris buffer (pH 6.8), and 10% 2-mercapto ethanol,
and separated using NuPage 12% bis-tris SDS PAGE gels
in MES running buffer (Invitrogen, Carlsbad, CA) and vis-
ualized by staining gels with coomassie blue. Proteins
were reduced, alykylated and trypsin digested in isolated
gel fragments, and were identified using LC/MS/MS.
Protein identification by 2D-DIGE was performed by
Applied Biomics (http://www.appliedbiomics.com/
index.html. Hayward, CA). Purified proteins were labeled
with either Cy3 or Cy5. The first dimension separation
consisted of isoelectric focusing over pH 3-10. The second
dimension separation was carried out using 8-14% gradi-
ent SDS-PAGE. Differentially expressed proteins were cut
out and digested with trypsin before analysis with mass
spectroscopy.
Results
The CTLA-4-specific monoclonal antibodyAS32 isolates 
B7-binding proteins from blood
In order to provide a more detailed biochemical character-
ization of sCTLA-4 from human plasma, we used the puri-
fication scheme depicted in Figure 1 with specific details
given in the Methods section. The purification scheme
required large quantities of human plasma. Therefore, we
collected discarded plasma from patients receiving plas-
mapheresis as part of a therapy to treat myasthenia gravis.
This provided a safe means of obtaining large volumes of
plasma from humans. We collected samples from three
patients that tested positive in CTLA-4 ELISA assays and
one patient that tested negative. The plasma was used to
perform biochemical analyses of CTLA-4 immunoreactive
material and no relationship to disease was studied.
Eluted material was collected in fractions and tested in
sandwich ELISA assays for CTLA-4 epitopes and for func-
tional activity in a B7 binding assay. Figure 2 shows the
results of experiments from three distinct plasma samples.
Peak reactivity with CTLA-4 specific antibodies correlates
with binding to the B7.1 protein. The specificity of the
binding to B7.1 was verified when the isolated material
did not bind to an irrelevant fusion protein (Muc-Ig).
Schema for isolating sCTLA-4 from human blood Figure 1
Schema for isolating sCTLA-4 from human blood. 1) 
Crude plasma was passed over a Q sepharose column to 
remove albumin and other contaminants. 2) Material that did 
not bind Q sepharose was concentrated by ammonium sul-
fate precipitation. 3) Concentrated material was passed over 
an antibody column containing an irrelevant monoclonal anti-
body against MOPC. 4) MOPC column flow through was 
passed over a column containing the CTLA-4 specific anti-
body AS32. Bound material was then eluted and collected.BMC Immunology 2009, 10:51 http://www.biomedcentral.com/1471-2172/10/51
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Similar results were also obtained with the B7.2-Ig fusion
protein (Figure 3), demonstrating that material eluted
from anti-CTLA-4 affinity columns binds to CTLA-4 lig-
ands. When the plasma samples lacking CTLA-4 immuno-
reactive material were subjected to an identical affinity
purification procedure, eluted material displayed mini-
mal reactivity in CTLA-4 ELISA and did not bind either
B7.1 or B7.2 (Figure 3).
Identification of proteins enriched by an AS32 column
Proteins eluted from anti-CTLA-4 affinity columns, were
separated by one-dimensional SDS-PAGE and visualized
with coomassie blue staining. Figure 4 shows a represent-
ative experiment comparing proteins isolated from
plasma that either lacked or contained anti-CTLA-4
immunoreactive material. The ~ 150 kDa band marked by
a box is enriched in anti-CTLA-4 reactive samples from 3
different donors (not shown) compared to the anti-CTLA-
4 negative sample. Proteins in the highlighted gel frag-
ment were identified by LC/MS/MS and are listed in Table
1. Protein sequencing was performed on material isolated
from 2 different positive donors. A light chain from a hep-
atitis B specific antibody was the only protein common to
both samples.
Recombinant sCTLA-4 and anti-CTLA-4 affinity-purified 
material from human plasma differentially bind protein A 
and have different molecular masses
In an effort to remove contaminating immunoglobulin
from the molecules recognized by anti-CTLA-4 antibod-
ies, we passed plasma through columns linked to protein
A. Unexpectedly, CTLA-4 immunoreactive material from
plasma bound to the protein A column and was only
Material that binds B7.1 and B7.2 can only be isolated from  blood that contains molecules recognized by CTLA-4 specific  antibodies Figure 3
Material that binds B7.1 and B7.2 can only be isolated 
from blood that contains molecules recognized by 
CTLA-4 specific antibodies. Plasma from subjects 17 
(CTLA-4 negative) and 19 (CTLA-4 positive) were passed 
over a column linked to the CTLA-4 specific antibody AS32. 
Material that eluted from the column under stringent wash 
conditions was collected in fractions, and was used to coat 
the wells of a 96 well plate. In panel (A) these wells were 
probed with the CTLA-4 specific antibody AS33. Panel (B) 
shows the binding of B7.1-Ig, B7.2-Ig, and Muc-Ig to the 
coated wells.
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Molecules that bind B7.1 can be isolated from plasma 
using CTLA-4 specific antibodies. CTLA-4 positive 
plasma, from subjects 19 (A), 22 (B), and 44 (C), were passed 
through a column linked to the CTLA-4 specific antibody 
AS32. Fractions, containing material that eluted from the col-
umn at low pH, were bound to 96 well plates and tested for 
interaction with various biotinylated proteins by ELISA: B7.1-
Ig (gray bars), Muc-Ig (black bars), and the AS33 antibody 
(circles).
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released at low pH (5B-D). In comparison, recombinant
sCTLA-4 that passed over protein A columns was present
in flow- through and in the neutral pH column wash solu-
tion, but it did not elute at low pH (Figure 5A). This indi-
cates that the CTLA-4 immunoreactive material in blood
exhibits immunoglobulin like properties in contrast to
recombinant sCTLA-4.
In addition, the finding that a CTLA-4-specific affinity col-
umn enriched a 150 kDa plasma protein (Figure 4) was
surprising given the primary sequence of sCTLA-4 predicts
its mass to be 23 kDa. In an effort to determine the molec-
ular mass of CTLA-4 immunoreactive material by a sec-
ond method, we performed gel filtration on serum and
tested fractions in ELISA assays using CTLA-4 specific anti-
bodies. Human IgG served as an internal size standard.
Blood-derived CTLA-4 immunoreactive material co-
eluted with the bulk of IgG indicating that it has a molec-
ular mass of approximately 150 kD (Figure 6A). This
result was repeated in samples obtained from 5 other
donors whose blood reacts with CTLA-4 specific antibod-
ies (not shown).
For comparison, serum from a donor lacking molecules
recognized by CTLA-4 specific antibodies was spiked with
recombinant sCTLA-4 and then passed over a sizing col-
umn. Recombinant sCTLA-4 clearly eluted from the col-
umn after IgG (Figure 6B). The minimal overlap of the IgG
fractions with fractions containing recombinant sCTLA-4
demonstrates that recombinant sCTLA-4 is smaller than
150 kD.
2D gel electrophoresis and mass spectroscopy of proteins 
enriched on an anti-CTLA-4 affinity column
Because molecules purified by anti-CTLA-4 affinity chro-
matography exhibit biochemical properties similar to
human IgG, we attempted to separate this material from
IgG using 2 dimensional gel electrophoresis that separates
molecules on the basis of isoelectric point and size. For
comparison, molecules that bound to a column contain-
ing an immobilized irrelevant antibody (MOPC), and
molecules bound to the AS32 column, were labeled with
different color fluorescent molecules and separated on the
same gel. The fluorescent dyes allowed identification of
proteins that were enriched by the AS32 column. 17 spots,
which were at least 2-fold more abundant in the AS32
eluted material versus the MOPC material, were analyzed
by mass spectroscopy, and their identity is shown in Table
2. There were no common proteins identified in this anal-
Table 1: LC/MS/MS identification of proteins in the 150 kd band unique to subjects testing positive in ELISA using CTLA4 specific 
antibodies.
Subject Protein ID Accession Number % Sequence Coverage
19 Chain A, Human Factor Vii C2 domain GI |15825659 32.7
19 Protein NIG51 lambda Bence-Jones GI |223229 30.6
19 Ig heavy chain V-III region CAM GI |123847 38.5
19 Immunoglobulin heavy chain [homo sapiens] GI |10334553 39.8
19 Unnamed protein product GI |28317 11.3
19 Anti HBs antibody light-chain Fab fragment [homo sapiens] GI |11275330 35.0
19 Unnamed protein product [homo sapiens] GI |34527640 33.4
19 Keratin 1 [homo sapiens] GI |17318569 15.7
44 Ig A L GI |229536 21.8
44 Anti HBs antibody light-chain Fab fragment [homo sapiens] GI |11275330 26.3
44 IGHG1 protein [homo sapiens] GI |50925957 29.4
44 Keratin 1 GI |17318569 8.7
44 IGHM protein [homo sapiens] GI |33873884 7.3
44 Keratin type I cytoskeletal 9 [homo sapiens] GI |81175178 8.7
1D SDS-PAGE analysis of material captured by a CTLA-4  specific affinity column Figure 4
1D SDS-PAGE analysis of material captured by a 
CTLA-4 specific affinity column. CTLA-4 negative 
plasma (donor 17) and CTLA-4 positive plasma (donor 19) 
were passed through a column linked to the CTLA-4 specific 
antibody AS32. Material was eluted at low pH and collected 
into fractions that were separated by 1D-SDS PAGE. 
Coomassie blue staining was used to visualize protein pat-
terns. A box marks the single band enriched in donor 19 
compared to donor 17.
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ysis when compared to mass spectroscopy performed on
bands identified on SDS-PAGE gels (Figure 4 and Table
1). Interestingly, we found another light chain from an
antibody specific for hepatitis B surface antigen. The anti-
Hepatitis B surface antigen light chains identified by the 1
dimensional and 2 dimensional protocols are distinct
light chains as they only share 30% sequence similarity
(not shown).
Discussion
Our biochemical analyses demonstrate that the molecules
in human blood that are recognized by anti-CTLA-4 anti-
bodies are not a simple product of the sCTLA-4 alternate
transcript. We previously described sCTLA-4 immunore-
active material in blood plasma from patients with
autoimmune thyroid disease [22]. In that study, Western
blotting of material from immunoprecipitates, using a
pool of commercially available monoclonal antibodies to
CTLA-4, identified proteins with a molecular mass of 23
kDa consistent with the size of recombinant sCTLA-4. We
also noted the observation of larger material (> 100 kDa)
in those immunopreciptates but did not characterize this
species further. The CTLA-4 immunoreactive material
described in this communication may be the larger mole-
cules noted in our previous studies.
This study identifies material that reacts with multiple
anti-CTLA-4 antibodies and with known ligands of CTLA-
Size exclusion chromatography separates recombinant  sCTLA-4 from blood-derived CTLA-4 immunoreactive mate- rial Figure 6
Size exclusion chromatography separates recom-
binant sCTLA-4 from blood-derived CTLA-4 immu-
noreactive material. A) Following gel filtration, fractions 
of CTLA-4 positive serum were analyzed with the sCTLA-4 
specific antibodies AS32 (coating antibody) and AS33 
(reporter antibody) and with antibodies specific for human 
IgG. B) Anti-CTLA-4 (BNI3 coat/AS33 reporter) ELISA and 
anti-human IgG ELISA were used to analyze fractions of 
CTLA-4 negative serum mixed with recombinant sCTLA-4 
after separation by gel filtration. Circles represent CTLA-4 
ELISA, and squares represent human IgG ELISA.
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Protein A binds blood-derived molecules that contain CTLA- 4 epitopes, but does not interact with recombinant sCTLA-4 Figure 5
Protein A binds blood-derived molecules that con-
tain CTLA-4 epitopes, but does not interact with 
recombinant sCTLA-4. Recombinant CTLA-4 (A) and 
plasma from CTLA-4 ELISA positive donors 19 (B), 22 (C) 
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and fractions eluted at low pH (E1, E2, E3, and E4) were ana-
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(capture), grey bars represent AS32 (coat)/AS33B (capture), 
and white bars anti-MOPC (coat)/AS33B (capture).
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4, B7.1 (CD80) and B7.2 (CD86). Additionally, its molec-
ular size is approximately 150 kDa, it binds protein A with
high affinity, and when analyzed by mass spectroscopy,
we find human antibodies. Despite the fact that the mol-
ecules studied exhibit characteristics of CTLA-4-Ig fusion
proteins, none of our plasma donors received exogenous
CTLA-4-Ig (Orencia) as a therapy. Therefore the isolated
molecules are endogenous to our plasma donors.
Though we did not conclusively identify these molecules,
we found 2 separate light chains that originated from
human immunoglobulins specific for Hepatitis B surface
antigen (Tables 1 and 2). One of the Hepatitis B specific
light chains was found in 2 different subjects, and both
light chains were isolated from a single donor. While it is
possible that we have identified an idiotype network
involving epitopes on the Hepatitis B surface antigen,
CTLA-4, and some immunoglobulins, comparing the
sequences with the bl2seq program on the NCBI website
http://www.ncbi.nlm.nih.gov/ did not reveal any obvious
sequence homology among these molecules. A more
detailed structural analysis is warranted.
Perhaps most importantly, our findings highlight the fact
that the sCTLA-4 measured in human plasma by studies of
autoimmune disease does not represent a simple gene
product of the sCTLA-4 transcript. Though the isolated
material was recognized by several CTLA-4 specific anti-
bodies and interacted with B7.1 and B7.2 proteins, mass
spectroscopy analysis found no evidence of the CTLA-4
protein in the isolated material. It is possible that CTLA-4
protein escaped our mass spectroscopy analysis. As shown
in figure 4, only a 150 kDa protein was more abundant in
samples that are positive by CTLA-4 ELISA than in the neg-
ative sample. sCTLA-4, having a mass of 23 kDa, may be
present in the very abundant band at approximately 23
kDa, but there was no evidence that this band was
enriched during our isolation procedure. Because of the
abundant material at ~ 23 kDa and ~ 50 kDa in both the
positive and negative samples we realized it was possible
that less abundant proteins may be obscured if they comi-
grated with more abundant proteins. Therefore, we chose
to analyze the samples by 2D-DIGE in an effort to resolve
sCTLA-4 from contaminating abundant proteins. Compu-
ter analysis identified the proteins most highly enriched
by the CTLA-4 specific affinity column, and again sCTLA-
4 was not found even when proteins of approximately 23
kDa were analyzed (figure 7 and table 2).
Our gel filtration and protein A binding data suggest that
if sCTLA-4 exists in the blood samples we analyzed, it
appears to be complexed with immunoglobulin. Another
possibility is that blood contains protein(s), either immu-
noglobulins or a novel protein associated with immu-
noglobulins, that interact with the ligands of CTLA-4 and
with CTLA-4 specific antibodies.
We believe the presence of CTLA-4 immunoreactivity in
plasma is not likely due to heterophile antibodies that are
known to interfere with two site immunoassays [30,31].
The samples selected for analysis in these studies were
screened to be negative for binding to irrelevant mouse
IgG. Furthermore, the Muc-Ig negative control used in the
B7 binding assays contained the identical Ig fusion part-
Table 2: Mass Spectroscopy Identification of Proteins Enriched by Affinity Purification of Plasma with a CTLA4 Affinity Column and 
Analyzed by 2D-DIGE
Spot Fold Increase As32:MOPC Protein Name Accession No.
1 3.2 Plasminogen GI |38051823
2 1.9 Plasminogen GI |38051823
3 2.8 Plasminogen GI |38051823
4 3.5 Immunoglobulin heavy chain GI |10334573
5 4.8 Immunoglobulin heavy chain GI |10334573
6 2.1 hypothetical protein GI |34365168
7 1.9 hypothetical protein GI |34365168
8 5.7 This CDS feature is included GI 1684931
9 6.2 complement C1q subcomponent, α GI |54781353
10 5.0 complement C1q subcomponent, α GI |54781353
11 8.2 immunoglobulin lambda light chain C region GI |386813
12 2.4 Unknown (protein for MGC:31941) GI |18044245
13 5.4 Chain B, Globular Head Of The Complement System GI |38492827
14 2.2 anti HBs antibody light-chain Fab GI |11275326
15 2.4 α-Entamoeba histolytica immunoglobulin κ light chain GI |5360675
16 3.2 IGLC1 protein GI |20380868
17 2.2 anti HBs antibody light-chain Fab GI |11275326
Plasma proteins that preferentially bound a to the CTLA4 specific antibody AS32 compared to the irrelevant control antibody MOPC were 
identified by 2D-DIGE. Spots were picked and identified by MALDI spectroscopy.BMC Immunology 2009, 10:51 http://www.biomedcentral.com/1471-2172/10/51
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ner as the B7-Ig proteins. Finally, if present, heterophile
antibodies should have been removed by the MOPC col-
umn during the isolation procedure.
Our findings may reconcile the apparent discrepancy
between reports of elevated levels of sCTLA-4 in plasma
from patients with autoimmune disease and the report of
decreased levels of the sCTLA-4 transcript among individ-
uals with the CT60 allele of the CTLA-4 gene. CT60 is a
single nucleotide polymorphism within the CTLA-4 locus
[18] and the "G" allele is associated with both susceptibil-
ity to Type 1 diabetes and low levels of the sCTLA-4 tran-
script. Because sCTLA-4 in blood is probably not the direct
product of the sCTLA-4 transcript, the lack of correlation
between transcript and plasma protein, is not surprising.
In addition, immunoassays designed to measure sCTLA-4
levels may not reliably quantify blood-derived sCTLA-4
because of its uncertain identity. In this regard, it is impor-
tant to interpret reports of sCTLA-4 levels with caution,
and to re-examine the possible relationship of circulating
CTLA-4 levels and human disease. To this point, we have
recently reported a lack of association between levels of
sCTLA-4 protein in blood and several of the common pol-
ymorphisms that show population genetic associations
with a variety of autoimmune disease [32].
Conclusion
Molecules from human blood that have been labeled
sCTLA-4 are not simply a direct product of an alternatively
spliced transcript of the CTLA-4 gene. These molecules
exhibit properties of CTLA-4 and of immunoglobulins.
Though some studies have found a correlation between
circulating levels of the putative sCTLA-4 molecule and
the presence of autoimmunity, this relationship is poorly
understood. This study improves understanding of the
biochemical nature of what has been called sCTLA-4 and
will help subsequent analyses to elucidate the role of this
molecule in autoimmune disorders.
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